glp-1 drugs for weight loss covered by insurance Perspectives from employers on the costs and issues associated with covering agonists Cigna is ending employee coverage

[DOI] [PubMed] [Google Scholar] 928.Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W

Blood Sugar Effects Both medications improve glucose metabolism: Liraglutide: HbA1c reduction of 0.5-1.0% at weight loss doses Originally developed for diabetes (Victoza) Modest glucose benefits at Saxenda doses Semaglutide: HbA1c reduction of 1.0-1.8% at diabetes doses Greater glucose improvement than liraglutide Significant benefit for prediabetes and diabetes For patients with diabetes or prediabetes, semaglutide provides greater metabolic benefit

In a drug safety update, published on 28 January 2025, the MHRA cited findings of a recent European Medicines Agency (EMA) review of the available evidence for all GLP-1 and dual GIP/GLP-1 RAs, which concluded that data supports an association between the medicines and the potential risk of pulmonary aspiration during anaesthesia or deep sedation, owing to the delayed gastric emptying linked to these medicines

On October 2, the FDA formally removed them from its official drug shortage list

Milicevic Z, Anglin G, Harper K, Konrad RJ, Skrivanek Z, Glaesner W, et al

What We Can Say Safely Energy use is still being studied